相关实验视频

Updated: May 16, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

用于治疗HR+/HER2-乳腺癌的Vepdegestrant

Toru Mukohara¹

¹Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Expert opinion on pharmacotherapy

|April 3, 2025

概括

一种新的口服PROTAC ER降解剂Vepdegestrant对先进的HR+/HER2-乳腺癌,特别是ESR1突变的乳腺癌有前途. 目前正在进行临床试验,以确认其有效性和克服内分泌抵抗的潜力.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

先进的激素受体阳性 (HR+) /人类表皮生长因子受体2-阴性 (HER2-) 乳腺癌治疗改善了内分泌疗法 (ET) 和向药物.
内分泌疗法耐药性,特别是由于ESR1突变,仍然是一个重要的临床挑战.

研究的目的:

为了评估vepdegestrant,一个新的PROteolysis TTargeting Chimera (PROTAC) 雌激素受体 (ER) 降解剂,用于晚期HR+/HER2-乳腺癌.
评估德格斯特兰特的安全性和有效性,包括其在不同ESR1基因型的潜在活性.

主要方法:

维普德格斯特兰是第一类,口服生物可用的PROTAC ER降解剂.
进行了临床前研究和I/II期临床试验,以评估其作为单剂和组合疗法的活性,安全性和有效性.

主要成果:

临床前数据表明,无论ESR1突变状态如何,Vepdegestrant活动都存在.
第I/II期研究表明,对毒毒剂的安全性概况良好,有效性令人鼓舞.

结论:

维普德格斯特兰特证明了作为高级HR+/HER2乳腺癌的新疗法选择的潜力,解决了对内分泌抵抗的未满足需求.
目前正在进行的第三阶段试验 (VERITAC-2) 将提供关于韦普德格斯特兰特的临床意义及其将PROTAC作为一种新类抗癌药物建立潜力的关键数据.

关键词:

这是一种ARV-471病毒.乳腺癌是什么? 乳腺癌是什么它是HER2阴性的.这就是PROTAC.具有激素受体阳性的人.这是一个巨大的转移.

更多相关视频

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

A Hormone-responsive 3D Culture Model of the Human Mammary Gland Epithelium

A Hormone-responsive 3D Culture Model of the Human Mammary Gland Epithelium

Published on: February 7, 2016

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...